In the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1.(currently amended) A compound of formula (I)



(I)

wherein

X is N;

Y is CH_2NR_2, NR_2CO, $CONR_2$, NR_2SO_2 or NR_2CONR_2

wherein R_2 is H or C_1-C_6 alkyl;

R_1 is H, C_1-C_6 alkyl or C_3-C_6 cycloalkyl;

R_3 is $(CH_2)_n$-phenyl, wherein the phenyl ~~may be mono or di substituted with R_4 and/or R_5~~ is monosubstituted with R_4 or disubstituted with R_4 and R_5;

wherein R_4 is selected from

~~a) H,~~

~~b) C_1-C_6 alkyl,~~

~~c) C_3-C_6 cycloalkyl,~~

~~d) halogen,~~

~~e) CN,~~

~~f) CF_3,~~

~~g) OH,~~

~~h) C_1-C_6 alkoxy,~~

~~i) NR_6R_7,~~

~~j) OCF_3,~~

~~k) SO_3CH_3,~~

~~l) SO_3CF_3,~~

~~m) $SO_2NR_6R_7$,~~

~~n) phenyl,~~

~~o) phenyl C_1-C_6 alkyl,~~

~~p) phenoxy,~~

~~q) C_1-C_6 alkylphenyl,~~

~~r)~~ a) an optionally substituted 5-, 6- or 7-membered heterocyclic ring containing one or two heteroatoms selected from N, O, S, SO and SO_2, wherein when the heterocyclic ring is 5- or 6-membered and contains one heteroatom, the heteroatom is not N and when the heterocyclic ring is 5- or 6-membered and contains two heteroatoms, the heteroatoms are not both N and wherein the substituent(s) is(are) selected from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, phenyl-C_1-C_6 alkyl, $(CH_2)_mOR_9$ wherein m is 2-6 and R_9 is H, C_1-C_6 alkyl, C_3-C_6 cycloalkyl or phenyl-C_1-C_6 alkyl, and COR_8, and

~~c)~~ b) an optionally substituted 5- or 6-membered heteroaromatic ring containing one or two heteroatoms selected from N, O and S, wherein when the heteroaromatic ring contains one heteroatom, the heteroatom is not N and when the heteroaromatic ring contains two heteroatoms, the heteratoms are not both N and wherein the substituent(s) is (are) selected from C_1-C_6 alkyl, C_3-C_6 cycloalkyl and phenyl-C_1-C_6 alkyl;~~, and~~

~~t) COR_8,~~

~~wherein R_6 is H, C_1-C_6 alkyl or C_3-C_6 cycloalkyl; R_7 is H, C_1-C_6 alkyl or C_3-C_6 cycloalkyl; and R_8 is C_1-C_6 alkyl, C_3-C_6 cycloalkyl, CF_3, NR_6R_7, or phenyl;~~

R_5 is selected from ~~H,~~ OH, CF_3, OCF_3, halogen, C_1-C_6 alkyl and C_1-C_6 alkoxy;

and n is 0-4;

wherein the compound is an (*R*)-enantiomer, an (*S*)-enantiomer, or a racemate in the form of a free base or a pharmaceutically acceptable salt or solvate thereof.

2. (previously presented) The compound according to claim 1 wherein Y is NR_2CO or $CONR_2$.

3. (cancelled)

4. (previously presented) The compound according to claim 1, wherein R_1 is H or C_1-C_6 alkyl.

5. (cancelled)

6. (cancelled)

7. (currently amended) The compound according to claim ~~6~~ 1, wherein n is 0.

8. cancelled

9. (currently amended) The compound according to claim ~~1~~ 2, wherein Y is NR_2CO.

10. (currently amended) The compound according to claim 1 wherein Y is NR_2CO and R_4 is morpholino ~~or COR_8~~.

11. (cancelled)

12. (previously presented) A pharmaceutical formulation comprising as active ingredient a therapeutically effective amount of the compound of claim 1 as an enantiomer or racemate, in the form of a free base or a pharmaceutically acceptable salt or solvate thereof optionally in association with diluents, excipients or inert carriers.

13. (previously presented) A method for the treatment of 5-hydroxytryptamine-mediated disorders, comprising administering to a patient in need of such treatment a

therapeutically effective amount of the pharmaceutical formulation of claim 12.

14-26. (cancelled)

27. (previously presented) A method for the treatment of 5-hydroxytryptamine mediated disorders comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound defined in claim 1.

28. (previously presented) A method for the treatment of 5-hydroxytryptamine-mediated disorders in the central nervous system which require treatment with an h5-HT_{1B} antagonist, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound defined in claim 1.

29. (previously presented) A process for the preparation of the compound of formula I according to claim 1, comprising:

A(i)

acylation, in the case wherein R_1 is C_1-C_6 alkyl or C_3-C_6 cycloalkyl, Y is NR_2CO, R_2 is hydrogen and X and R_3 are as

defined in claim 1, of a compound of formula **A**,



(A) (I)

with an activated carboxylic acid R_3-$COLg_1$ wherein Lg_1 is a leaving group; or with a carboxylic acid R_3-COOH and an activating reagent;

A(ii)

acylation, in the case wherein R_1 is hydrogen, Y is NR_2CO, R_2 is hydrogen, R_c is a protecting group and X and R_3 are as defined in claim 1, of a compound of formula **B**



(B) (I)

with an activated carboxylic acid R_3-$COLg_1$ wherein Lg_1 is a

leaving group; or with a carboxylic acid R_3-COOH and an activating reagent, and removing the protecting group R_c;

A(iii)

debenzylation, in the case wherein R_1 is C_1-C_6 alkyl or C_3-C_6 cycloalkyl, X and R_2 are as defined in claim 1 and R_9 below is C_1-C_6 alkyl, C_3-C_6 cycloalkyl, $(CH_2)_mOH$ wherein m is 2-6, or COR_8, of a compound of formula Ia, followed by a) hydrogenation, b) alkylation, c) alkylation and removal of a protecting group or d) acylation;



(Ia) (I)

B(i)

reacting ,in the case wherein R_1 is C_1-C_6 alkyl or C_3-C_6 cycloalkyl, Y is $CONR_2$, and X, R_2 and R_3 are as defined in claim 1, an activated carboxylic

acid of a compound of formula C;



(C) (I)

with an aniline or an amine HNR_2R_3; or

B(ii)

reacting, in the case wherein R_1 is hydrogen, Y is NR_2CO, R_c is a protecting group and X, R_2 and R_3 are as defined in claim 1, an activated carboxylic acid of a compound of formula D



(D) (I)

with an aniline or an amine HNR_2R_3, and removing the protecting group R_c; or

c

reacting, in the case wherein R_1 is C_1-C_6 alkyl or C_3-C_6 cycloalkyl, Y is NR_2CONR_2, R_2 is hydrogen and X and R_3 are as defined in claim 1, a compound of formula A,



(A) (I)

with a suitable azide in the presence of a carboxylic acid, R_3COOH.

30. (previously presented) A compound of the formula



wherein

X=N;

Z=NH_2 or COOH; and

R_1 is H, C_1-C_6 alkyl or C_3-C_6 cycloalkyl.